RxDoctor Payments Data

Preeti Pal, NP

Nurse Practitioner · Bakersfield, CANPI 1942960851

Payments from drug & device makers

$3,463in general payments, 2019–2025

Across 161 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$669
  • Fresenius USA Marketing, Inc.$541
  • Amgen$352
  • AstraZeneca$337
  • Calliditas Therapeutics US Inc.$287
  • Bayer$246
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,44399%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,463 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$40,570
Medicare patients
281
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide35$110,356
Sevelamer Carbonate73$56,063
ProsolParenteral Amino Acid 20% No.185$13,868
VeltassaPatiromer Calcium Sorbitex23$12,984
Calcium Acetate69$4,342
Midodrine Hcl17$2,390
Cinacalcet Hcl11$916
Hydralazine Hcl44$476
Nifedipine ErNifedipine15$349
Calcitriol53$301
Amlodipine Besylate46$164
Ciprofloxacin Hcl56$153
Losartan Potassium23$131
Clonidine Hcl24$104
Furosemide34$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$541$110,35635 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →